SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs10033900

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Multicenter Study on the Investigation of Previously Verified Leading Gene Polymorphisms Related to Age-related Macular Degeneration in Turkish Population

The purpose of this study is to determine whether common genetic polymorphisms that have been verified to be related to age-related macular degeneration (AMD) in some populations are also associated with AMD in Turkish population

NCT02248324 Age-related Macular Degeneration
MeSH: Macular Degeneration

In the introduced projects study, the relationship of eight different gen polymorphisms (CFH rs1061170 and rs1410996, LOC387715 / ARMS2 gene rs10490924, C2 gene rs9332739, CFB gene rs641153, CFI rs10033900 , HTRA-1 gene rs11200638, C3 rs2230199) will be studied in 2800 patients with high risk intermediate and late stage AMD and 2200 age-matched control subjects.

Primary Outcomes

Description: Gene polymorphisms of 8 region with identification of homozygous, heterozygote and wild type genotyping and alleles

Measure: rate of homozygous, heterozygous or wild type genotype and allels

Time: at the end of third years

Secondary Outcomes

Measure: Odds ratios for each genotyping in healthy elderly controls and patients with age related macular degeneration

Time: at the end of third years

Other Outcomes

Measure: Odds ratios for various combinations of gene regions between healthy elderly control and patients with age related macular degeneration

Time: at the end of third years


HPO Nodes